EU Review Gets Under Way For Curative Vision Loss Gene Therapy
US Filing Of GenSight’s Lumevoq Will Come Later, In H2 2021
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
Vifor Pharma has resubmitted a marketing application for avacopan to the European Medicines Agency – this time for an unconditional approval.
Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.